8-K: Aptose Biosciences Converts Debt to Equity with Hanmi Pharmaceutical, Amends Investor Rights Agreement

Aptose Biosciences Inc. converts $1.5 million of debt into equity with Hanmi Pharmaceutical and amends investor rights agreement to include board observer rights and registration rights.

Summary

• Aptose Biosciences Inc. entered into a Debt Conversion Agreement with Hanmi Pharmaceutical Co., Ltd. on March 18, 2025, converting $1,513,533.10 of debt into 409,063 common shares at $3.70 per share.
• The conversion price is based on the average closing price of Aptose's common shares on Nasdaq for the five trading days prior to the agreement.
• Aptose and Hanmi also amended and restated their Investor Rights Agreement, granting Hanmi certain rights, including the right to designate an employee to work at Aptose and customary registration rights.
• Hanmi is entitled to four demand registrations and piggyback registration rights.
• The interest payments owed to Hanmi for the period commencing on December 21, 2024 and ending on March 31, 2025 may be made on or before the final closing date of the Capital Raise and shall not be considered an event of default under the Facility Agreement is such interest payments are made no later than June 27, 2025.
• Additional debt conversions are available at Hanmi's discretion after a capital raise, subject to conditions including an ownership threshold not exceeding 19.99%.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The debt conversion strengthens the balance sheet and the amended agreement solidifies a key investor relationship. However, dilution of existing shareholders and reliance on future capital raises introduce some uncertainty.

Positives

• The debt conversion reduces Aptose's outstanding debt by $1,513,533.10.
• The amended Investor Rights Agreement strengthens the relationship with a key investor, Hanmi Pharmaceutical.
• Hanmi's continued investment signals confidence in Aptose's future prospects.
• The agreement allows Aptose to delay interest payments until June 27, 2025, provided they are made before the final closing date of the Capital Raise.

Negatives

• The debt conversion dilutes existing shareholders' equity by issuing 409,063 new common shares.
• Hanmi's right to designate an employee could potentially influence Aptose's operations.
• Failure to pay the Interest Payments would constitute an event of default under the Facility Agreement.

Risks

• Future debt conversions are subject to Hanmi's discretion and certain conditions, which may not be met.
• The success of Aptose's future capital raises is uncertain.
• The market price of Aptose's common shares could fluctuate, impacting the value of Hanmi's investment.
• The company aims to raise fifteen million United States Dollars (USD) (USD 15,000,000) (the Capital Raise), not including the amount being converted pursuant to this Agreement, through At-the-Market offerings, Committed Equity Facility, and/or private and/or public offerings following the Company's filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the Commission) or equivalent.

Future Outlook

Aptose plans to raise $15 million through various offerings and may convert additional debt into equity after the capital raise, subject to certain conditions.

Industry Context

Debt-to-equity conversions are a common financing strategy for biotech companies, especially those with promising technology but limited cash flow. This move allows Aptose to strengthen its balance sheet and potentially attract new investors.

Comparison to Industry Standards

• The debt conversion price of $3.70 per share is based on the average closing price of Aptose's common shares on Nasdaq for the five trading days prior to the agreement, which is a standard practice.
• The investor rights granted to Hanmi are also typical for significant investors in publicly traded companies, including registration rights and board observer rights.
• Similar companies such as XOMA Corporation have used debt conversion strategies to manage their capital structure.

Related Party Transactions

• The debt conversion and amended investor rights agreement constitute related party transactions between Aptose and Hanmi Pharmaceutical, a significant investor.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new common shares.
• Employees may be impacted by the addition of a Hanmi-designated employee.
• The company's financial stability is improved by the debt reduction.

Next Steps

• Aptose will issue the Conversion Shares to Hanmi Pharmaceutical.
• Aptose will assist Hanmi in obtaining necessary permits for their nominee to work at Aptose.
• Aptose and Hanmi will enter into a separate service agreement outlining the terms of the Hanmi Nominee's appointment.
• Aptose will pursue a capital raise of $15 million through various offerings.
• Hanmi may convert additional debt into equity after the capital raise, subject to certain conditions.

Key Dates

Keywords

debt conversion, investor rights agreement, Hanmi Pharmaceutical, Aptose Biosciences, equity, common shares, registration rights, capital raise